Keto-CTA plaque growth matched diabetics' and far exceeded high-risk statin-treated groups
Louis quotes an analysis of the Keto-CTA trial putting its plaque progression in context: median non-calcified plaque rose 18.8 mm3 in one year, comparable to type 2 diabetics (~17.4 mm3/yr), about triple PARADIGM metabolically normal people, and nearly 3x SMARTool high-risk non-statin users (6.4 mm3/yr). PAV rose 0.8% overall and 2.4% in those with CAC over 100.